The 56-gene ctDNA panel is a key component of DefineMBC™, the company’s comprehensive blood biopsy for metastatic breast cancerSAN DIEGO (BUSINESS WIRE) Epic Sciences, Inc. announced today that the company’s 56-gene ctDNA panel for genomic profiling of metastatic breast cancer is covered by the MolDX program (admi.
San Diego-based Epic Sciences has raise $24M in a Series G funding, the company said last week. According to the company, the funding was co-led by Deerfield Management and Arsenal Capital Partners, a
Funding will accelerate commercial launch of DefineMBC™SAN DIEGO (BUSINESS WIRE) Epic Sciences, Inc. (“Epic” or “Epic Sciences”), a privately held diagnostics company, has completed a $24 million Series G which together with its $43 million Series F financing, totals $67 million raised in the last twelve months. T.